Otowa-Suematsu Natsu, Sakaguchi Kazuhiko, Yamada Tomoko, Nishisaka Marika, Morita Yasuko, Fukumitsu Hayato, Katsura Yukari, Okada Yuko, Hirota Yushi, Sugawara Kenji, Ogawa Wataru
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Division of Community Medicine and Medical Education, Department of Social/Community Medicine and Health Science, Kobe University Graduate School of Medicine, Kobe, Japan.
BMJ Open Diabetes Res Care. 2025 Aug 31;13(5):e005255. doi: 10.1136/bmjdrc-2025-005255.
The metal-chelating activity of metformin, which has long been known but of unclear clinical relevance, has recently been implicated in the pleiotropic effects, including antitumorigenic and anti-inflammatory actions, of the drug. However, whether metformin actually influences metal dynamics in humans has remained unknown. We here investigate whether metformin influences serum metal levels in individuals with type 2 diabetes.
In this cross-sectional study, individuals with type 2 diabetes treated or not treated with metformin for at least 6 months were recruited. The primary outcome was the difference in serum copper concentration between metformin users and non-users. Secondary outcomes included differences in serum levels of iron, zinc, and vitamin B as well as in copper-related and iron-related parameters between the two groups.
A total of 189 individuals (93 metformin users and 96 non-users) were analyzed. Metformin users showed significantly lower serum copper (16.0 vs 17.8 µmol/L, p<0.001) and iron levels (16.3 vs 17.3 µmol/L, p=0.02) and higher zinc levels (13.3 vs 12.5 µmol/L, p=0.01) compared with non-users. Copper-related and iron-related parameters for metformin users were consistent with latent deficiencies of these metals. Serum homocysteine levels (12.2 vs 11.2 µmol/L, p=0.03) were significantly higher, whereas vitamin B levels (338.7 vs 412.8 pmol/L, p<0.001) were significantly lower, in metformin users. Multiple regression analysis including variables that potentially influence metal dynamics identified metformin use as an independent predictor of serum copper (B = -1.54 µmol/L, p<0.001) and iron levels (B = -2.49 µmol/L, p=0.004).
Metformin use was associated with reduced serum levels of copper and iron, as well as with increased serum zinc levels. These changes in metal dynamics may be related to the pharmacological effects of this widely administered drug.
二甲双胍的金属螯合活性早已为人所知,但临床相关性尚不清楚,最近它被认为与该药物的多效性作用有关,包括抗肿瘤和抗炎作用。然而,二甲双胍是否真的会影响人体中的金属动态仍不清楚。我们在此研究二甲双胍是否会影响2型糖尿病患者的血清金属水平。
在这项横断面研究中,招募了接受或未接受二甲双胍治疗至少6个月的2型糖尿病患者。主要结局是二甲双胍使用者与非使用者之间血清铜浓度的差异。次要结局包括两组之间血清铁、锌和维生素B水平以及与铜和铁相关参数的差异。
共分析了189名个体(93名二甲双胍使用者和96名非使用者)。与非使用者相比,二甲双胍使用者的血清铜(16.0对17.8µmol/L,p<0.001)和铁水平(16.3对17.3µmol/L,p=0.02)显著降低,锌水平(13.3对12.5µmol/L,p=0.01)显著升高。二甲双胍使用者的铜相关和铁相关参数与这些金属的潜在缺乏一致。二甲双胍使用者的血清同型半胱氨酸水平(12.2对11.2µmol/L,p=0.03)显著更高,而维生素B水平(338.7对412.8pmol/L,p<0.001)显著更低。包括可能影响金属动态的变量的多元回归分析确定,使用二甲双胍是血清铜(B = -1.54µmol/L,p<0.001)和铁水平(B = -2.49µmol/L,p=0.004)的独立预测因素。
使用二甲双胍与血清铜和铁水平降低以及血清锌水平升高有关。这些金属动态变化可能与这种广泛使用的药物的药理作用有关。